Prognostic Significance of Nuclear Factor Kappa B Expression in Locally Advanced Cervical Cancer Patients Treated Definitively with Concurrent Chemoradiation

Basel Altoos, Christina Small, Prarthana Dalal, Darlene Attieh, Samar El Achy, Vamsi Parimi, Jian Jun Wei, Irene Helenowski, Eric D. Donnelly, Jonathan Strauss, William Small, Tamer Refaat*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Objectives:Nuclear factor kappa B (NFkB) is a transcription factor shown to confer treatment resistance in tumors. A previous report suggested an association between pretreatment NFkB and poorer outcomes for cervical cancer patients treated with chemoradiation therapy (CRT). We aimed to validate their findings in a larger patient cohort.Materials and Methods:This Institutional Review Board approved study included patients with locally advanced cervical cancer patients treated with CRT. Evaluation of both nuclear and cytoplasmic immunoreactivity for NFkB was scored semiquantitatively by 3 pathologists. Cytoplasmic positivity incorporated both the intensity and percentage of immunoreactivity in invasive carcinoma (H-score), whereas nuclear positivity was assessed by percentage of positive cells. Outcomes were stratified by NFkB overexpression and tumor characteristics. Overall survival (OS), progression-free survival (PFS), distant metastases-free survival (DMFS), and local regional control (LC) were obtained using Kaplan-Meier and differences between groups were evaluated by the log-rank test. Hazard ratios were obtained using Cox regression for both univariate and multivariate analyses.Results:The mean age was 51 years old and most (78.57%) had locally advanced disease. Five-year OS, PFS, LC, and DMFS in the entire cohort were 57.18% (confidence interval [CI], 34.06%-74.82%), 48.07% (CI, 25.50%-67.52%), 72.11% (CI, 49.96%-85.73%), and 62.85% (CI, 36.33%-80.82%), respectively. There was no significant association between NFkB expression (H-index ≥180) and 3-year and 5-year OS (P-value=0.34), PFS (P-value=0.21), LC (P-value=0.86), or DMFS (P-value=0.18).Conclusions:Our study demonstrated that cytoplasmic NFkB-p65 expression (H-index ≥180) was associated with a nonstatistically significant trend toward poor clinical outcomes in locally advanced cervical cancer patients treated definitively with CRT.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume43
Issue number1
DOIs
StatePublished - Jan 1 2020

    Fingerprint

Keywords

  • cervical cancer
  • concurrent chemoradiation
  • nuclear transcription factor kappa B

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this